Loading
NASDAQHealthcareBiotechnology
Latest quote
$0.7599
−$0.014 · -1.81%
Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipeline includes promising candidates such as GEM-AKI, which is being developed as a potential therapy for both the prevention and management of acute kidney injury, and GEM-CKD, intended for the prevention and treatment of chronic kidney disease. Established in 2019, this San Diego, California-based enterprise was formerly known as Petra Acquisition, Inc., before officially adopting the name Revelation Biosciences, Inc. in January 2022.
Previous close
$0.7599
−$0.014 · -1.81%
Regular session · ET · Market data may be delayed.
Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipeline includes promising candidates such as GEM-AKI, which is being developed as a potential therapy for both the prevention and management of acute kidney injury, and GEM-CKD, intended for the prevention and treatment of chronic kidney disease. Established in 2019, this San Diego, California-based enterprise was formerly known as Petra Acquisition, Inc., before officially adopting the name Revelation Biosciences, Inc. in January 2022.
Day range
Current $0.7599
52-week range
Current $0.7599
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
50
Fair Value
Sentiment
57
Mixed
Risk
69
High Risk
Momentum
24
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipeline includes promising candidates such as GEM-AKI, which is being developed as a potential therapy for both the prevention and management of acute kidney injury, and GEM-CKD, intended for the prevention and treatment of chronic kidney disease. Established in 2019, this San Diego, California-based enterprise was formerly known as Petra Acquisition, Inc., before officially adopting the name Revelation Biosciences, Inc. in January 2022.
Day range
Current $0.7599
52-week range
Current $0.7599
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 27.06K USD | 27.92K USD | 25.05K USD | 40.01K USD | — |
| Gross profit | −27.06K USD | −27.92K USD | −25.05K USD | −40.01K USD | — |
| Research and development | 4.06M USD | 3.55M USD | 4.15M USD | 5.38M USD | 6.91M USD |
| Selling, general, and administrative | 5.01M USD | 4.43M USD | 4.51M USD | 5.49M USD | 5.04M USD |
| Operating expenses | 9.07M USD | 7.98M USD | 8.66M USD | 10.86M USD | 11.95M USD |
| Interest expense | — | — | — | — | 41.76K USD |
| Depreciation and amortization | 27.06K USD | 27.92K USD | 25.05K USD | 25.05K USD | 16.78K USD |
| Operating income | −9.07M USD | −7.98M USD | −8.66M USD | −10.86M USD | −11.95M USD |
| Net income | −8.91M USD | −15.04M USD | −120.25K USD | −10.83M USD | −11.99M USD |
Company facts updated Oct 11, 2026.
Recent quarterly results
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jan 28, 2026 | 1:4 | — | — |
Stock split | Jul 7, 2025 | 1:3 | — | — |
Stock split | Jan 28, 2025 | 1:16 | — | — |
Stock split | Jan 25, 2024 | 1:30 | — | — |
Stock split | Feb 1, 2023 | 1:35 | — | — |
Effective Jan 28, 2026
1:4
Effective Jul 7, 2025
1:3
Effective Jan 28, 2025
1:16
Effective Jan 25, 2024
1:30
Effective Feb 1, 2023
1:35
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
